

**bs-41407R**

**[ Primary Antibody ]**

## **SARS-CoV-2 (2019-nCoV) Spike RBD Rabbit pAb**



www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

### — DATASHEET —

|   |                     |  |
|---|---------------------|--|
| <b>Host:</b> Rabbit   | <b>Isotype:</b> IgG | <b>Applications:</b> ELISA (1:5000-10000)  |
| <b>Clonality:</b> Polyclonal  |                     | <b>Reactivity:</b> (predicted: SARS-CoV-2) |
| <b>Target:</b> SARS-CoV-2 (2019-nCoV) Spike RBD   |                     |  |
| <b>Purification:</b> affinity purified by Protein A   |                     |  |
| <b>Concentration:</b> 1mg/ml  |                     | <b>Predicted MW.:</b> 75/140 kDa           |
| <b>Storage:</b> 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.<br>Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.  |                     |  |
| <b>Background:</b> The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct. |                     |  |

### — SELECTED CITATIONS —

- **[IF=7.666]** Qianling Su. et al. Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein. CELLS-BASEL. 2022 Jan;11(21):3355 WB ;Escherichia coli. 36359751